问题 阅读理解与欣赏

梅香

林清玄

      (1)一个有钱的富人,正在自家的花园里赏梅花。

      (2)那是冬日寒冷的清晨,艳红的梅花正以最美丽的姿容吐露,富人颇为自己的花园里能开出这样美丽的梅花,而感到无比的快慰。

     (3)突然,门外传来敲门的声音,富人去开了门,发现一个衣衫褴褛的乞丐,在寒风里冻得直打抖,那乞丐已在这开满梅花的园外冻了一夜,他说:“先生,行行好,可不可以给我一点东西吃。”    

     (4)富人请乞丐在园门口稍稍等候,转身进入厨房,端来一碗热腾腾的饭菜,他布施给乞丐的时候,乞丐忽然说:“先生,您家里的梅花,真是非常芳香呀!”说完了,转身走出去。

     (5)富人呆立在那里,感到非常震惊,他震惊的是:穷人也会赏梅花吗?这是自己从来不知道的。另一个震惊的是,花园里种了几十年的梅花,为什么自己从来没有闻到过梅花的芳香呢?

     (6)于是,他小心翼翼地,以一种庄严的心情,深怕惊动梅香似的悄悄走近梅花,他终于闻到了梅花那含蓄的、清澈的、澄明无比的芬芳,然后他濡湿的眼睛,流下了感动的泪水,为自己第一次闻到梅花的芳香。

      (7)是的,乞丐也能赏梅花,乞丐也能闻到梅花的香气,有的乞丐甚至在极饥饿的情况下,还能闻到梅花清明的气息。

      (8)可见得,好的物质条件不一定能使人成为有品位的人,而坏的物质条件也不会遮蔽人精神的清明,一个人没有钱是值得同情的,一个人一生都不知道梅花的香气一样值得悲悯。

      (9)一个人的品质其实是与梅香相似,是无形的,是一种气息,我们如果光是欣赏花的外形,就很难知道梅花有极淡的清香;我们如果不能细心地体会,也难以品味到一个人隐在外表内部的人格香气。

     (10)最可叹息的是,很少有人能回观自我,品赏自己心灵的梅香,大部分人空过了一生,也没有体会到隐藏在心灵内部极幽微,但极清澈的自性的芳香。

     (11)能闻到梅香的乞丐也是富有的人。

     (12)现在,让我们一起以一种庄严的心情,走到心灵的花园,放下一切的缠缚,狂心都歇,观闻从我们自性中流露的梅香吧!

1、用简明的文字概括本文叙述的故事。

                                                                                                                                           

2、请用文中相关的语句回答:富人听了乞丐的话感到震惊,他震惊的是什么?

                                                                                                                                                      

3、文章题为“梅香”,请结合第(8)、(9)段谈谈“梅香”指的是什么?

                                                                                                                                                       

4、在生活中,我们也许并不富有,也许常被人漠视,但我们也有“自己心灵的梅香”。读了本文,请谈谈你的感受。

                                                                                                                                                              

                                                                                                                                                             

答案

1、乞丐闻到梅花的芳香,富人为此感到震惊,富人也是第一次闻到梅花的芳香。

2、穷人也会赏梅花或者乞丐也能闻到梅花的香气;富人自己种了了十年的梅花,却从来没闻到过梅花的芳香。

3、精神的清明或内部的人格香气。

4、“略”

单项选择题
单项选择题

In 2010, a federal judge shook America’s biotech industry to its core. Companies had won patents for isolated DNA for decades—by 2005 some 20% of human genes were parented. But in March 2010 a judge ruled that genes were unpatentable. Executives were violently agitated. The Biotechnology Industry Organisation (BIO), a trade group, assured members that this was just a "preliminary step" in a longer battle.

On July 29th they were relieved, at least temporarily. A federal appeals court overturned the prior decision, ruling that Myriad Genetics could indeed holb patents to two genes that help forecast a woman’s risk of breast cancer. The chief executive of Myriad, a company in Utah, said the ruling was a blessing to firms and patients alike.

But as companies continue their attempts at personalised medicine, the courts will remain rather busy. The Myriad case itself is probably not over Critics make three main arguments against gene patents: a gene is a product of nature, so it may not be patented; gene patents suppress innovation rather than reward it; and patents’ monopolies restrict access to genetic tests such as Myriad’s. A growing number seem to agree. Last year a federal task-force urged reform for patents related to genetic tests. In October the Department of Justice filed a brief in the Myriad case, arguing that an isolated DNA molecule "is no less a product of nature.., than are cotton fibres that have been separated from cotton seeds. "

Despite the appeals court’s decision, big questions remain unanswered. For example, it is unclear whether the sequencing of a whole genome violates the patents of individual genes within it. The case may yet reach the Supreme Court.

As the industry advances, however, other suits may have an even greater impact. Companies are unlikely to file many more patents for human DNA molecules I most are already patented or in the public domain. Firms are now studying how genes interact, looking for correlations that might be used to determine the causes of disease or predict a drug’s efficacy, companies are eager to win patents for ’connecting the dits’, explains Hans Sauer, a lawyer for the BIO.

Their success may be determined by a suit related to this issue, brought by the Mayo Clinic, which the Supreme Court will hear in its next term. The BIO recently held a convention which included seddions to coach lawyers on the shifting landscape for patents. Each meeting was packed.

According to Hans Sauer, companies are eager to win patents for()

A. establishing disease correlations

B. discovering gene interactions

C. drawing pictures of genes

D. identifying human DNA